Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trialXavier Leleu, Amine Kasmi, Cyrille Hulin et al.|Nature Medicine|2024Cited by 109
Carfilzomib weekly 20/56 mg/m<sup>2</sup>, lenalidomide and dexamethasone for early relapsed refractory multiple myelomaValentine Richez, Xavier Leleu, Vincent Javaugue et al.|American Journal of Hematology|2018Cited by 7
Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics: the IFM 2014-01 studyArthur Bobin, Xavier Leleu, Salomon Manier et al.|Haematologica|2024Cited by 3